Pirifur (Phenazopiridine, Nalidixic Acid)
Active Ingredient: Nalidixic Acid, Phenazopyridine
Dosage: 500 mg/50 mg
Route of Administration: Oral
Dosage Form: Tablets
Quantity per package: 24
Availability: Out of stock
Pirifur is prescribed in pain relief in urological diseases’ symptoms. It is used as emergency assistance. It is prescribed to treat urinary tract infections. It guarantees fast relief.
Pirifurbut is currently unavailable but you can find similar pain relievers here.
Pirifur is indicated for the treatment of urinary infections and concomitant symptoms, produced by gram-negative microorganisms sensitive to nalidixic acid including E. coli, Enterobacter sp, Klebsiella sp and most Proteus sp.
Dosage and administration
Initial therapy (acute conditions, 7 to 14 days): 2 tablets every 6 hours. Maintenance therapy (chronic conditions, more than 14 days): 2 tablets every 8 hours in symptomatic patients or 2 tablets every 12 hours in asymptomatic patients. Take 2 tablets at once. It is recommended to administer this drug on an empty stomach, preferably one hour before meals.
Pirifur should not be administered to patients with known hypersensitivity to nalidixic acid or related compounds, with a history of seizures or porphyria, or to children under 1 year of age. Because of its phenazopyridine content, its use is contraindicated in liver and kidney failure.
The reactions reported after administration of Pirifur tablets included drowsiness, weakness, headache, paraesthesia and vertigo. Rarely, patients complained of subjective and reversible visual disturbances. These reactions included photosensitivity, change in color perception, difficulty focusing, decreased visual acuity and diplopia. These alterations disappeared when the treatment was suspended. In rare cases, patients experienced toxic psychosis or mild seizures (mainly in geriatric patients who have received an overdose or who are predisposed to these effects). Neonatal and pediatric patients receiving therapeutic doses of nalidixic acid had an occasional elevation of intracranial pressure with bulging of the anterior fontanel, papilledema and headache. A few patients had sixth cranial nerve paralysis. Even if the mechanisms of these reactions are unknown, the signs and symptoms usually disappear quickly after discontinuation of treatment. Other side effects: cholestasis, metabolic acidosis, thrombocytopenia, leukopenia or hemolytic anemia that may be associated with a difference in the activity of glucose-6-phosphate dehydrogenase.
Methemoglobinemia may occur in patients with associated susceptibility. Hemolytic anemia and liver and / or renal toxicity can also be observed. Treatment: these reactions are usually short-lived, due to the rapid excretion of the medication. If overdose is detected, it is recommended to perform gastric lavage. If absorption has already occurred, it is recommended to administer abundant fluids and establish supportive measures such as oxygen or artificial respiration. Although there is no data on the use of anticonvulsant therapy, it can be indicated in severe cases.
Cross-resistance has been observed between Pirifur and other quinolones (such as oxolinic acid) but this has not been observed with other antibiotics. Nalidixic acid can increase the effects of oral anticoagulants such as warfarin to bishydroxycoumarin, through a considerable displacement of plasma albumin binding sites.